US Patent 3,461,204 Scope, Claims, and U.S. Patent Landscape

Executive summary: No complete, accurate analysis can be produced from the provided input because the claim text is not included. Without the full claim set (independent and dependent claims) and the remaining bibliographic fields (inventor/assignee, filing and issue dates, and the patent’s title/summary), the scope and enforceable subject matter for US 3,461,204 cannot be determined, nor can a reliable U.S. landscape (related continuations, related reissues, prosecution history implications, terminal disclaimers, or citation-driven family boundaries) be mapped.

What exactly are the claims in US Patent 3,461,204 and how do they define scope?

Featured-snippet answer: US 3,461,204 scope cannot be determined because the claim text is not provided.

Which claim types drive protection (product, composition, method, or use)?

Answer: Cannot be classified without the claims.

Independent claims vs dependent claims

Answer: Cannot be analyzed without the claim list.

Functional limitations, ranges, and “comprising” language

Answer: Cannot be analyzed without the claim language.

How broad is the claim interpretation likely to be in U.S. courts?

Answer: Cannot be assessed without the claim language and specification/definitions incorporated by reference.

How many other patents are in the same family as US 3,461,204 in the United States?

Featured-snippet answer: Cannot be quantified from the provided input.

Are there continuations, divisional filings, or reissues that expand or narrow claims?

Answer: Not determinable without the patent family record (application numbers and related U.S. publications/patents).

What are the key assignees and inventors tied to the estate?

Answer: Not determinable without bibliographic data.

What is the Orange Book status of US Patent 3,461,204 for its drug application?

Featured-snippet answer: Not determinable from the provided input.

Which NDA or ANDA listing would reference this patent?

Answer: Requires the drug product, application number, and Orange Book patent listing.

What Orange Book “patent type” applies (drug substance, drug product, method of use)?

Answer: Requires Orange Book listing metadata.

When does exclusivity end if US 3,461,204 is tied to an approved NDA?

Featured-snippet answer: Not determinable without identifying the NDA and the listed patent terms.

Does the patent expire before or after regulatory exclusivity?

Answer: Requires expiration date and exclusivity start/end dates.

What formulations are protected by US Patent 3,461,204 (if it is a composition patent)?

Featured-snippet answer: Not determinable.

Which dosage forms or delivery systems are claimed (tablet, capsule, injectable, sustained release)?

Answer: Not determinable without claim text and title.

Are stabilizers, carriers, or process conditions claimed with material limitations?

Answer: Not determinable without claim text.

What method-of-use or treatment claims are covered by US Patent 3,461,204?

Featured-snippet answer: Not determinable.

Is the claim directed to a regimen, patient selection, dosing schedule, or biomarker?

Answer: Not determinable without claim language.

How would infringement be evaluated under U.S. claim construction?

Answer: Cannot be mapped without claim text and key terms.

Which companies could have potential freedom-to-operate risk from US Patent 3,461,204?

Featured-snippet answer: Cannot be determined from the provided input.

Do generic or biosimilar entrants face design-around constraints?

Answer: Cannot be assessed without knowing the protected subject matter and the relevant drug product.

What patent litigation or PTAB activity involves US Patent 3,461,204?

Featured-snippet answer: Cannot be determined from the provided input.

Have there been IPRs, PGRs, or district court cases targeting this patent?

Answer: Not determinable without procedural history references.

How strong is the patent estate around US 3,461,204 based on citations and overlapping claims?

Featured-snippet answer: Cannot be evaluated without the patent’s title/subject matter and the claims.

Are there earlier-priority patents that narrow novelty, or later patents that reinforce scope?

Answer: Requires citation and family boundary data.

Key Takeaways

No scope or enforceable claim interpretation for US Patent 3,461,204 can be produced because the claims are not included.
No U.S. landscape mapping (family size, continuations, related patents, litigation, Orange Book linkage, or exclusivity timelines) can be performed without the patent’s bibliographic and claim content.

FAQs

What is the expiration date of US 3,461,204 and does it differ from regulatory exclusivity?
Does US 3,461,204 claim a composition, a formulation, or a method-of-use, and how does that affect infringement risk?
What prior art most directly impacts novelty and obviousness for US 3,461,204?
If a Paragraph IV challenge is filed against the NDA/ANDAs connected to US 3,461,204, what claim elements would be pivotal?
What design-around strategies would typically reduce infringement for the claim categories used in US 3,461,204?

References

No sources are included because the required claim text and bibliographic fields for US Patent 3,461,204 were not provided.

Title:	Method of treating hepatic encephalopathy
Abstract:
Inventor(s):	Johannes Bircher
Assignee:	US Philips Corp
Application Number:	US632193A
Patent Claim Types: see list of patent claims
Patent landscape, scope, and claims:	US Patent 3,461,204 Scope, Claims, and U.S. Patent Landscape Executive summary: No complete, accurate analysis can be produced from the provided input because the claim text is not included. Without the full claim set (independent and dependent claims) and the remaining bibliographic fields (inventor/assignee, filing and issue dates, and the patent’s title/summary), the scope and enforceable subject matter for US 3,461,204 cannot be determined, nor can a reliable U.S. landscape (related continuations, related reissues, prosecution history implications, terminal disclaimers, or citation-driven family boundaries) be mapped. What exactly are the claims in US Patent 3,461,204 and how do they define scope? Featured-snippet answer: US 3,461,204 scope cannot be determined because the claim text is not provided. Which claim types drive protection (product, composition, method, or use)? Answer: Cannot be classified without the claims. Independent claims vs dependent claims Answer: Cannot be analyzed without the claim list. Functional limitations, ranges, and “comprising” language Answer: Cannot be analyzed without the claim language. How broad is the claim interpretation likely to be in U.S. courts? Answer: Cannot be assessed without the claim language and specification/definitions incorporated by reference. How many other patents are in the same family as US 3,461,204 in the United States? Featured-snippet answer: Cannot be quantified from the provided input. Are there continuations, divisional filings, or reissues that expand or narrow claims? Answer: Not determinable without the patent family record (application numbers and related U.S. publications/patents). What are the key assignees and inventors tied to the estate? Answer: Not determinable without bibliographic data. What is the Orange Book status of US Patent 3,461,204 for its drug application? Featured-snippet answer: Not determinable from the provided input. Which NDA or ANDA listing would reference this patent? Answer: Requires the drug product, application number, and Orange Book patent listing. What Orange Book “patent type” applies (drug substance, drug product, method of use)? Answer: Requires Orange Book listing metadata. When does exclusivity end if US 3,461,204 is tied to an approved NDA? Featured-snippet answer: Not determinable without identifying the NDA and the listed patent terms. Does the patent expire before or after regulatory exclusivity? Answer: Requires expiration date and exclusivity start/end dates. What formulations are protected by US Patent 3,461,204 (if it is a composition patent)? Featured-snippet answer: Not determinable. Which dosage forms or delivery systems are claimed (tablet, capsule, injectable, sustained release)? Answer: Not determinable without claim text and title. Are stabilizers, carriers, or process conditions claimed with material limitations? Answer: Not determinable without claim text. What method-of-use or treatment claims are covered by US Patent 3,461,204? Featured-snippet answer: Not determinable. Is the claim directed to a regimen, patient selection, dosing schedule, or biomarker? Answer: Not determinable without claim language. How would infringement be evaluated under U.S. claim construction? Answer: Cannot be mapped without claim text and key terms. Which companies could have potential freedom-to-operate risk from US Patent 3,461,204? Featured-snippet answer: Cannot be determined from the provided input. Do generic or biosimilar entrants face design-around constraints? Answer: Cannot be assessed without knowing the protected subject matter and the relevant drug product. What patent litigation or PTAB activity involves US Patent 3,461,204? Featured-snippet answer: Cannot be determined from the provided input. Have there been IPRs, PGRs, or district court cases targeting this patent? Answer: Not determinable without procedural history references. How strong is the patent estate around US 3,461,204 based on citations and overlapping claims? Featured-snippet answer: Cannot be evaluated without the patent’s title/subject matter and the claims. Are there earlier-priority patents that narrow novelty, or later patents that reinforce scope? Answer: Requires citation and family boundary data. Key Takeaways No scope or enforceable claim interpretation for US Patent 3,461,204 can be produced because the claims are not included. No U.S. landscape mapping (family size, continuations, related patents, litigation, Orange Book linkage, or exclusivity timelines) can be performed without the patent’s bibliographic and claim content. FAQs What is the expiration date of US 3,461,204 and does it differ from regulatory exclusivity? Does US 3,461,204 claim a composition, a formulation, or a method-of-use, and how does that affect infringement risk? What prior art most directly impacts novelty and obviousness for US 3,461,204? If a Paragraph IV challenge is filed against the NDA/ANDAs connected to US 3,461,204, what claim elements would be pivotal? What design-around strategies would typically reduce infringement for the claim categories used in US 3,461,204? References No sources are included because the required claim text and bibliographic fields for US Patent 3,461,204 were not provided. More… ↓ ⤷ Start Trial

Details for Patent: 3,461,204

Summary for Patent: 3,461,204